Log in

NASDAQ:MGLNMagellan Health Competitors & Alternatives

$70.32
+0.73 (+1.05 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$69.61
Now: $70.32
$72.35
50-Day Range
$67.54
MA: $71.87
$76.92
52-Week Range
$30.60
Now: $70.32
$81.04
Volume69,430 shs
Average Volume195,390 shs
Market Capitalization$1.76 billion
P/E Ratio23.52
Dividend YieldN/A
Beta1.22

Competitors

Magellan Health (NASDAQ:MGLN) Vs. PEN, AMED, RGEN, ASND, TNDM, and CGC

Should you be buying MGLN stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Magellan Health, including Penumbra (PEN), Amedisys (AMED), Repligen (RGEN), Ascendis Pharma A/S (ASND), Tandem Diabetes Care (TNDM), and Canopy Growth (CGC).

Penumbra (NYSE:PEN) and Magellan Health (NASDAQ:MGLN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Penumbra and Magellan Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra7.04%5.72%4.28%
Magellan Health1.02%8.02%3.53%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Penumbra and Magellan Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra00503.00
Magellan Health01002.00

Penumbra presently has a consensus price target of $194.00, indicating a potential upside of 4.36%. Magellan Health has a consensus price target of $67.00, indicating a potential downside of 4.72%. Given Penumbra's stronger consensus rating and higher possible upside, analysts clearly believe Penumbra is more favorable than Magellan Health.

Institutional & Insider Ownership

83.7% of Penumbra shares are owned by institutional investors. Comparatively, 99.3% of Magellan Health shares are owned by institutional investors. 8.9% of Penumbra shares are owned by insiders. Comparatively, 14.1% of Magellan Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Penumbra and Magellan Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million11.91$48.46 million$0.98189.69
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85

Magellan Health has higher revenue and earnings than Penumbra. Magellan Health is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Penumbra has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Magellan Health (NASDAQ:MGLN) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Magellan Health and Amedisys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85
Amedisys$1.96 billion3.30$126.83 million$4.4045.28

Amedisys has lower revenue, but higher earnings than Magellan Health. Magellan Health is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Magellan Health has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Magellan Health and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health1.02%8.02%3.53%
Amedisys6.43%23.09%11.22%

Insider and Institutional Ownership

99.3% of Magellan Health shares are owned by institutional investors. Comparatively, 88.3% of Amedisys shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Magellan Health and Amedisys, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health01002.00
Amedisys04902.69

Magellan Health currently has a consensus price target of $67.00, indicating a potential downside of 4.72%. Amedisys has a consensus price target of $196.1538, indicating a potential downside of 1.54%. Given Amedisys' stronger consensus rating and higher probable upside, analysts plainly believe Amedisys is more favorable than Magellan Health.

Summary

Amedisys beats Magellan Health on 10 of the 14 factors compared between the two stocks.

Repligen (NASDAQ:RGEN) and Magellan Health (NASDAQ:MGLN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Insider & Institutional Ownership

89.1% of Repligen shares are held by institutional investors. Comparatively, 99.3% of Magellan Health shares are held by institutional investors. 1.5% of Repligen shares are held by insiders. Comparatively, 14.1% of Magellan Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Repligen and Magellan Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00513.17
Magellan Health01002.00

Repligen currently has a consensus target price of $136.6667, indicating a potential upside of 11.56%. Magellan Health has a consensus target price of $67.00, indicating a potential downside of 4.72%. Given Repligen's stronger consensus rating and higher possible upside, equities analysts clearly believe Repligen is more favorable than Magellan Health.

Earnings & Valuation

This table compares Repligen and Magellan Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million23.71$21.41 million$1.07114.50
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85

Magellan Health has higher revenue and earnings than Repligen. Magellan Health is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen and Magellan Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen8.11%5.55%4.28%
Magellan Health1.02%8.02%3.53%

Volatility & Risk

Repligen has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Summary

Repligen beats Magellan Health on 8 of the 15 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

99.3% of Magellan Health shares are held by institutional investors. 14.1% of Magellan Health shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Magellan Health and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health1.02%8.02%3.53%
Ascendis Pharma A/S-2,231.94%-36.56%-32.40%

Earnings and Valuation

This table compares Magellan Health and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85
Ascendis Pharma A/S$14.98 million430.21$-244,180,000.00($5.25)-25.58

Magellan Health has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Magellan Health and Ascendis Pharma A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health01002.00
Ascendis Pharma A/S001103.00

Magellan Health currently has a consensus price target of $67.00, suggesting a potential downside of 4.72%. Ascendis Pharma A/S has a consensus price target of $172.2727, suggesting a potential upside of 28.28%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Magellan Health.

Volatility & Risk

Magellan Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Magellan Health beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Tandem Diabetes Care (NASDAQ:TNDM) and Magellan Health (NASDAQ:MGLN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

91.7% of Tandem Diabetes Care shares are held by institutional investors. Comparatively, 99.3% of Magellan Health shares are held by institutional investors. 6.0% of Tandem Diabetes Care shares are held by insiders. Comparatively, 14.1% of Magellan Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Tandem Diabetes Care and Magellan Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care05702.58
Magellan Health01002.00

Tandem Diabetes Care currently has a consensus price target of $97.2308, indicating a potential upside of 1.40%. Magellan Health has a consensus price target of $67.00, indicating a potential downside of 4.72%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, research analysts plainly believe Tandem Diabetes Care is more favorable than Magellan Health.

Profitability

This table compares Tandem Diabetes Care and Magellan Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-4.22%-9.39%-5.51%
Magellan Health1.02%8.02%3.53%

Volatility & Risk

Tandem Diabetes Care has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tandem Diabetes Care and Magellan Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million15.91$-24,750,000.00($0.22)-435.86
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85

Magellan Health has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Summary

Magellan Health beats Tandem Diabetes Care on 10 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Canopy Growth (NYSE:CGC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares Magellan Health and Canopy Growth's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$7.16 billion0.25$55.90 million$3.7318.85
Canopy Growth$297.34 million20.41$-993,370,000.00$1.3213.11

Magellan Health has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Magellan Health and Canopy Growth, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health01002.00
Canopy Growth314502.09

Magellan Health presently has a consensus price target of $67.00, indicating a potential downside of 4.72%. Canopy Growth has a consensus price target of $31.9176, indicating a potential upside of 84.50%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Magellan Health.

Risk & Volatility

Magellan Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500.

Insider and Institutional Ownership

99.3% of Magellan Health shares are owned by institutional investors. Comparatively, 10.3% of Canopy Growth shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Magellan Health and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health1.02%8.02%3.53%
Canopy Growth-752.54%-20.66%-14.40%

Summary

Magellan Health beats Canopy Growth on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Penumbra logo
PEN
Penumbra
1.4$185.90+3.2%$6.73 billion$547.41 million170.55
Amedisys logo
AMED
Amedisys
1.3$199.22+4.3%$6.73 billion$1.96 billion51.88
Repligen logo
RGEN
Repligen
1.4$122.51+3.0%$6.69 billion$270.24 million272.25
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.7$134.29+2.0%$6.57 billion$14.98 million-25.20Analyst Downgrade
Analyst Revision
Heavy News Reporting
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.3$95.89+7.2%$6.26 billion$362.30 million-290.57
Canopy Growth logo
CGC
Canopy Growth
1.5$17.30+0.7%$6.11 billion$297.34 million-2.61
Bausch Health Companies logo
BHC
Bausch Health Companies
2.5$17.41+1.3%$6.10 billion$8.60 billion-3.25
Encompass Health logo
EHC
Encompass Health
2.5$61.30+1.6%$6.09 billion$4.61 billion17.77
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.4$93.87+0.4%$5.95 billion$3.07 billion25.65
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.1$105.55+1.0%$5.94 billion$2.16 billion21.94
Syneos Health logo
SYNH
Syneos Health
1.5$56.38+0.2%$5.87 billion$4.68 billion30.48Heavy News Reporting
Novocure logo
NVCR
Novocure
1.9$58.05+4.0%$5.87 billion$351.32 million645.07
SDGR
PPD
0.9$87.77+5.2%$5.85 billion$85.54 million0.00
SDGR
Schrodinger
0.8$92.36+1.2%$5.85 billionN/A0.00
ADPT
Adaptive Biotechnologies
1.3$44.18+4.0%$5.83 billion$85.07 million-25.10
VIR
Vir Biotechnology
0.7$50.22+3.0%$5.74 billionN/A0.00
LHC Group logo
LHCG
LHC Group
1.2$174.26+4.1%$5.73 billion$2.08 billion55.15
Crispr Therapeutics logo
CRSP
Crispr Therapeutics
1.2$86.23+3.8%$5.54 billion$289.59 million114.97
Novavax logo
NVAX
Novavax
1.5$104.32+9.5%$5.47 billion$18.66 million-25.20Analyst Revision
Acceleron Pharma logo
XLRN
Acceleron Pharma
2.1$96.04+4.1%$5.41 billion$73.99 million-37.08Insider Selling
ALLO
Allogene Therapeutics
1.3$40.48+5.8%$5.37 billionN/A-20.34
ONEM
1life Healthcare
1.5$38.06+9.3%$5.24 billion$276.26 million-13.40
United Therapeutics logo
UTHR
United Therapeutics
1.7$115.95+1.3%$5.17 billion$1.45 billion9.67
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.5$81.95+5.3%$5.15 billion$103.71 million-11.15
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$153.03+0.9%$5.13 billion$26.52 million-15.55Heavy News Reporting
Zai Lab logo
ZLAB
Zai Lab
1.3$85.04+2.3%$5.05 billion$12.98 million-28.07
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
0.9$113.26+1.5%$5.02 billion$3.34 million-17.45
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.4$91.33+3.2%$4.94 billion$1.11 billion70.25
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.4$46.13+3.5%$4.53 billion$168.80 million512.61
Globus Medical logo
GMED
Globus Medical
2.0$45.39+1.0%$4.47 billion$785.37 million31.30
Haemonetics logo
HAE
Haemonetics
1.6$87.83+0.4%$4.44 billion$988.48 million59.75
Spark Therapeutics logo
ONCE
Spark Therapeutics
1.1$113.57+0.0%$4.37 billion$64.72 million-53.82
Myokardia logo
MYOK
Myokardia
1.4$90.62+2.5%$4.37 billion$33.56 million-13.59
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.5$69.55+6.6%$4.34 billionN/A-5.51Analyst Revision
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$70.58+0.8%$4.33 billion$2.11 million-14.49Analyst Report
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.6$76.65+3.0%$4.28 billion$66.51 million-10.32Heavy News Reporting
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$23.36+2.9%$4.28 billion$114.62 million-8.95
MOR
MorphoSys
0.5$32.43+1.7%$4.22 billionN/A0.00
China Biologic Products logo
CBPO
China Biologic Products
0.7$106.55+0.1%$4.20 billion$503.70 million26.97
InVitae logo
NVTA
InVitae
1.1$32.81+2.0%$4.18 billion$216.82 million-10.32Insider Selling
Neogen logo
NEOG
Neogen
1.0$77.14+0.7%$4.09 billion$414.19 million68.88
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$33.44+2.6%$4.03 billion$23.87 million-11.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.04+3.3%$4.00 billion$182.24 million-11.57Insider Selling
Healthequity logo
HQY
Healthequity
1.4$57.91+3.7%$3.98 billion$531.99 million1,930.33High Trading Volume
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.6$132.19+3.2%$3.97 billion$311.33 million134.89
Integra Lifesciences logo
IART
Integra Lifesciences
1.9$46.34+0.3%$3.94 billion$1.52 billion149.48
Nevro logo
NVRO
Nevro
1.4$114.87+0.7%$3.88 billion$390.26 million-42.39
BBIO
BridgeBio Pharma
1.6$31.58+2.1%$3.86 billion$40.56 million-12.73
Premier logo
PINC
Premier
1.3$31.20+1.5%$3.86 billion$1.22 billion-2.97
Wright Medical Group logo
WMGI
Wright Medical Group
1.3$29.88+0.7%$3.85 billion$920.90 million-40.38
This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.